Pilot Study, Without Direct Individual Benefice, of Biological Effect of Tarceva (OSI-774) [Erlotinib] at Posology of 150 mg by Day for Patients Stricken by ENT Epidermoid Carcinoma Waiting for First Surgical Picking up

Trial Profile

Pilot Study, Without Direct Individual Benefice, of Biological Effect of Tarceva (OSI-774) [Erlotinib] at Posology of 150 mg by Day for Patients Stricken by ENT Epidermoid Carcinoma Waiting for First Surgical Picking up

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Head and neck cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top